Balance sheet of Glenmark Pharma is strong.
But short term working capital might become an issue for this company.

Yes, The debt of Glenmark Pharma is increasing.
Latest debt of Glenmark Pharma is -₹258.59 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹2,327.34 Crs.

The profit is oscillating.
The profit of Glenmark Pharma is -₹171.52 Crs for TTM, -₹1,501.67 Crs for Mar 2024 and ₹297 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Glenmark Pharma latest dividend payout ratio is 23.73% and 3yr average dividend payout ratio is 15.61%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Capital Work in Progress, Inventory, Short Term Loans & Advances